MxP® Quant 1000 assay

MxP Quant 1000 assay

Transform medicine with metabolomics

The new standard of excellence in quantitative metabolomics profiling

MxP® Quant 1000 delivers the most comprehensive quantitative measure of metabolism, setting a new standard of excellence for metabolomics profiling. High analytical precision is achieved from minimal sample volume, delivering deep biological insights for fundamental, pharmaceutical and clinical research. MxP® Quant 1000 empowers scientists to decipher chronic disease mechanisms and detect phenotypic changes, contributing to the development of innovative therapeutic solutions that will lead the transformation of medicine.

Extensive coverage

Broadest panel to address chronic disease
Cover 100s of pathways including
core human metabolism and microbiome

Instant insights

Large set of disease-specific indicators
Gain instant insights
with metabolite sums and ratios

Reliable and reproducible

Unprecedented level of precision
Rely on hundreds of tested
calibrators and internal standards

Cost-effective solution

Best sample volume to data points ratio
Quantify over 1,800 biomarkers
from only 40 µL of sample

MxP® Quant 1000 – One solution, many applications

Fundamental research

Holistic understanding of chronic disease mechanisms
Systems biology studies
Biomarker discovery
Population health | Cohorts
Metabotyping
Multiomics

Clinical | Pharmaceutical research

Prodromal biomarkers
Disease risk prediction
New drug targets
Patient stratification
Drug response prediction
Progression monitoring
Precision medicine

Consumer health

Personalized healthcare and nutrition
Health monitoring
Preventive measures
At-home sampling
Participatory medicine

MxP® Quant 1000 metabolite classes

Small molecule panel

Alkaloids (2)
Amine oxides (1)
Amino acids (20)
Amino acid-related (77)
Bile acids (24)
Biogenic amines (10)
Carboxylic acids (8)
Catechols (3)
Cresols (2)
Dicarboxylic acids (25)
Fatty acids (39)
Hormones and related (5)
Indoles and derivatives (18)
Nucleobases (5)
Nucleobase-related (14)
Nucleotides (2)
Organic acids (16)
Phenolic acids (22)
Phenoxy compounds (2)
Polyamines (7)
Pyridinecarboxylic acids (6)
Sugars (7)
Tricarboxylic acids (3)
Vitamins and cofactors (9)

Lipid panel

Acylcarnitines (40)
Ceramides (29)
Cholesteryl esters (22)
Diglycerides (41)
Dihexosylceramides (9)
Dihydroceramides (8)
Hexosylceramides (20)
Lysophosphatidic acids (8)
Lysophosphatidylcholines (12)
Lysophosphatidylethanolamines (43)
Lysophosphatidylglycerols (10)
Lysophosphatidylinositols (15)
Lysophosphatidylserines (12)
Monoglycerides (12)
Phosphatidic acids (41)
Phosphatidylcholines (76)
Phosphatidylethanolamines (95)
Phosphatidylglycerols (64)
Phosphatidylinositols (53)
Phosphatidylserines (18)
Sphinganines and sphingosines (8)
Sphinganine and sphingosine phosphates (8)
Sphingomyelins (14)
Triglycerides (242)
Trihexosylceramides (6)

Service projects at biocrates

From study planning to data integration – biocrates scientists support every step of your project

Request quote

The microbiome as gatekeeper of inflammation

In intestinal inflammation (IBD), serum Kynunerine/Tryptophane ratio is increased while absolute concentrations of microbial tryptophan metabolites such as 3-IPA are decreased. The conversion of kynurenine to 3-OH kynurenine is the first step towards synthesis of the pro-inflammatory and neurotoxic metabolite quinolinic acid (QUIN).

Many diseases are associated with changes in tryptophan metabolism

Alzheimer´s disease
Depression
Cancer
Cardiovascular disease
Liver disease
IBD

Microbial metabolism of tryptophan influences gut health and the immune system.

Gut inflammation is associated with decreased microbial tryptophan metabolism and increased kynurenine/tryptophan ratio.

The MxP® Quant 1000 assay enables scientists to investigate the impact of tryptophan metabolism on health by screening samples with metabolomics, leveraging data to access instant insights and translating results to develop innovative solutions for 5P medicine.

Energy crisis in Alzheimer’s disease

The TCA cycle is a crossroads for energy production beyond glucose and fatty acid metabolism. Amino acid catabolites feed into multiple steps of the pathway.

In early stages of Alzheimer’s disease, glycolysis is decreased in the brain while alternative energy sources (amino acids, ketone bodies) can still be used by neurons.

Amino acids were reduced in human serum and rat CSF, while levels of TCA cycle and glycolysis intermediates were elevated in human serum.

The MxP® Quant 1000 assay enables scientists to investigate the impact of energy metabolism on health by screening samples with metabolomics, leveraging data to access instant insights and translating results to develop innovative solutions for 5P medicine.

Dedicated assays for metabolomics and lipidomics

For applications where only small molecules or lipids are needed, metabolomics and lipid panels are available as separate assays.

MxQuant assay

Focus on small molecules

Benefits

Easy-to-interpret metabolomics
Deep insights into the effects of the microbiome on the host
Broad exploration of human and mammalian metabolism of small molecules

LxQuant assay

Focus on lipids

Benefits

Easy-to-interpret lipidomics
Deep insights into the metabolism of lipids
Broad screening for circulating lipids from lipoproteins, membrane lipids and storage lipids

Features

327 small molecules
24 chemical classes
291 biologically relevant sums and ratios

Features

906 lipids
25 chemical classes
334 biologically relevant sums and ratios

More Resources

biocrates blog articles, insights and more

5P medicine

5P medicine integrates molecular tools and modern science to shape future healthcare. Metabolomics, unlike genomics, reflects environmental influences.

More information

Metabolite of the month Citric acid

Slightly out of focus picture of the legs of marathon runners

Metabolite of the month is a series that offers a sneak peek into metabolomics. This month: Citric acid, a key player in energy production, bone health, and disease therapy.

Chronic diseases have a common origin

Focusing only on genomics, proteomics, and microbiomics leaves a gap in understanding complex chronic diseases. Metabolomics bridges this gap and transforms research.

Watch webinar